AG˹ٷ

STOCK TITAN

[SCHEDULE 13G/A] BioMarin Pharmaceuticals Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Viking Global and affiliated funds report a 6.4% common-stock stake in BioMarin Pharmaceuticals (BMRN). Collectively the Reporting Persons beneficially own 12,288,611 shares out of 192,001,650 shares outstanding as of June 30, 2025. Ownership is shared (no reported sole voting or dispositive power); the holdings are held across several Viking entities and funds (largest positions reported: Viking Global Investors LP 12,288,611; Viking Global Performance LLC 8,208,825; Viking Global Equities Master Ltd. 8,044,650; Viking Long Fund Master Ltd. 2,856,671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115). The filing states the securities were not acquired to change or influence control of the issuer. Signatures on the amendment are dated August 14, 2025.

Viking Global e fondi affiliati segnalano una partecipazione del 6,4% nel capitale ordinario di BioMarin Pharmaceuticals (BMRN). Complessivamente i dichiarante possiedono beneficiariamente 12.288.611 azioni su 192.001.650 azioni in circolazione alla data del 30 giugno 2025. La proprietà è condivisa (nessun potere di voto o dispositivo esclusivo dichiarato); le partecipazioni sono ripartite tra più entità e fondi Viking (posizioni maggiori riportate: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). Nel deposito si afferma che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente. Le firme sull'emendamento sono datate 14 agosto 2025.

Viking Global y fondos afiliados informan una participación del 6,4% en acciones ordinarias de BioMarin Pharmaceuticals (BMRN). En conjunto, las personas que informan poseen beneficiariamente 12.288.611 acciones de 192.001.650 acciones en circulación a 30 de junio de 2025. La propiedad es compartida (no se declara poder de voto o dispositvo exclusivo); las tenencias están distribuidas entre varias entidades y fondos de Viking (posiciones principales informadas: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). El documento indica que los valores no fueron adquiridos para cambiar o influir en el control del emisor. Las firmas en la enmienda están fechadas el 14 de agosto de 2025.

바이� 글로벌 � 계열 펀드가 바이오마� 파마슈티컬스(BMRN)� 보통� 6.4% 지분을 신고했습니다. 신고인들은 2025� 6� 30� 현재 발행주식 � 192,001,650� � 12,288,611주를 실질적으� 보유하고 있습니다. 소유권은 공동으로 보유되며(단독 의결� 또는 처분권은 신고되지 않음), 보유 지분은 여러 바이� 법인 � 펀드에 분산되어 있습니다(보고� 주요 보유: Viking Global Investors LP 12,288,611�; Viking Global Performance LLC 8,208,825�; Viking Global Equities Master Ltd. 8,044,650�; Viking Long Fund Master Ltd. 2,856,671�; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115�). 제출서류에는 해당 증권� 발행인의 지배권� 변경하거나 영향력을 행사하기 위해 취득� 것이 아니라고 명시되어 있습니다. 수정서에 대� 서명일자� 2025� 8� 14일입니다.

Viking Global et des fonds affiliés déclarent une participation de 6,4 % du capital ordinaire de BioMarin Pharmaceuticals (BMRN). Collectivement, les personnes déclarante détiennent effectivement 12 288 611 actions sur 192 001 650 actions en circulation au 30 juin 2025. La détention est partagée (aucun pouvoir de vote ou de disposition exclusif déclaré) ; les avoirs sont répartis entre plusieurs entités et fonds Viking (principales positions déclarées : Viking Global Investors LP 12 288 611 ; Viking Global Performance LLC 8 208 825 ; Viking Global Equities Master Ltd. 8 044 650 ; Viking Long Fund Master Ltd. 2 856 671 ; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1 223 115). Le dépôt indique que ces titres n'ont pas été acquis dans le but de modifier ou d'influencer le contrôle de l'émetteur. Les signatures de l'amendement sont datées du 14 août 2025.

Viking Global und angeschlossene Fonds melden einen Stammaktienanteil von 6,4% an BioMarin Pharmaceuticals (BMRN). Zusammen besitzen die meldenden Personen wirtschaftlich 12.288.611 Aktien von insgesamt 192.001.650 ausstehenden Aktien zum 30. Juni 2025. Das Eigentum wird geteilt (kein alleiniges Stimm- oder Verfügungsrecht angegeben); die Bestände sind auf mehrere Viking-Einheiten und -Fonds verteilt (größte gemeldete Positionen: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). In der Einreichung wird angegeben, dass die Wertpapiere nicht zum Zweck des Wechsels oder der Beeinflussung der Kontrolle des Emittenten erworben wurden. Die Unterschriften der Änderung sind auf den 14. August 2025 datiert.

Positive
  • Material ownership disclosed: Reporting Persons collectively report 12,288,611 shares, equal to 6.4% of outstanding common stock, improving market transparency.
  • Structured disclosure across entities: The filing breaks down holdings by each Viking entity and names involved individuals, clarifying allocation of shared voting and dispositive power.
  • Certification of passive intent: Reporting Persons certify the securities were not acquired to change or influence control, indicating no announced activism.
Negative
  • None.

Insights

TL;DR A coordinated disclosure shows Viking-affiliated entities hold a material 6.4% stake in BioMarin, reported as shared beneficial ownership.

The filing documents that multiple Viking funds and management-affiliated individuals may be deemed beneficial owners of 12,288,611 BioMarin shares, representing 6.4% of the reported outstanding common stock (192,001,650). The ownership is recorded as shared voting and dispositive power across entities rather than sole control. The filing includes the required joint-filing agreement and a certification that the position is not intended to influence control. For investors, this is a material ownership disclosure that increases transparency about a sizable passive position but contains no statements of intent or plans that would indicate an active campaign or control attempt.

TL;DR Material passive stake disclosed; no sole voting/dispositive power and no stated intent to exert control.

The Schedule 13G/A shows Viking-affiliated reporting persons and three Executive Committee members may be deemed to beneficially own the same 12,288,611 shares. All reported holdings are identified as shared voting and shared dispositive power; each named individual reports no sole authority. The filing includes the standard certification that the shares were not acquired to change or influence issuer control. From a governance perspective, this disclosure clarifies potential influence channels but does not indicate an active governance campaign or change in board/control intentions.

Viking Global e fondi affiliati segnalano una partecipazione del 6,4% nel capitale ordinario di BioMarin Pharmaceuticals (BMRN). Complessivamente i dichiarante possiedono beneficiariamente 12.288.611 azioni su 192.001.650 azioni in circolazione alla data del 30 giugno 2025. La proprietà è condivisa (nessun potere di voto o dispositivo esclusivo dichiarato); le partecipazioni sono ripartite tra più entità e fondi Viking (posizioni maggiori riportate: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). Nel deposito si afferma che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente. Le firme sull'emendamento sono datate 14 agosto 2025.

Viking Global y fondos afiliados informan una participación del 6,4% en acciones ordinarias de BioMarin Pharmaceuticals (BMRN). En conjunto, las personas que informan poseen beneficiariamente 12.288.611 acciones de 192.001.650 acciones en circulación a 30 de junio de 2025. La propiedad es compartida (no se declara poder de voto o dispositvo exclusivo); las tenencias están distribuidas entre varias entidades y fondos de Viking (posiciones principales informadas: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). El documento indica que los valores no fueron adquiridos para cambiar o influir en el control del emisor. Las firmas en la enmienda están fechadas el 14 de agosto de 2025.

바이� 글로벌 � 계열 펀드가 바이오마� 파마슈티컬스(BMRN)� 보통� 6.4% 지분을 신고했습니다. 신고인들은 2025� 6� 30� 현재 발행주식 � 192,001,650� � 12,288,611주를 실질적으� 보유하고 있습니다. 소유권은 공동으로 보유되며(단독 의결� 또는 처분권은 신고되지 않음), 보유 지분은 여러 바이� 법인 � 펀드에 분산되어 있습니다(보고� 주요 보유: Viking Global Investors LP 12,288,611�; Viking Global Performance LLC 8,208,825�; Viking Global Equities Master Ltd. 8,044,650�; Viking Long Fund Master Ltd. 2,856,671�; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115�). 제출서류에는 해당 증권� 발행인의 지배권� 변경하거나 영향력을 행사하기 위해 취득� 것이 아니라고 명시되어 있습니다. 수정서에 대� 서명일자� 2025� 8� 14일입니다.

Viking Global et des fonds affiliés déclarent une participation de 6,4 % du capital ordinaire de BioMarin Pharmaceuticals (BMRN). Collectivement, les personnes déclarante détiennent effectivement 12 288 611 actions sur 192 001 650 actions en circulation au 30 juin 2025. La détention est partagée (aucun pouvoir de vote ou de disposition exclusif déclaré) ; les avoirs sont répartis entre plusieurs entités et fonds Viking (principales positions déclarées : Viking Global Investors LP 12 288 611 ; Viking Global Performance LLC 8 208 825 ; Viking Global Equities Master Ltd. 8 044 650 ; Viking Long Fund Master Ltd. 2 856 671 ; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1 223 115). Le dépôt indique que ces titres n'ont pas été acquis dans le but de modifier ou d'influencer le contrôle de l'émetteur. Les signatures de l'amendement sont datées du 14 août 2025.

Viking Global und angeschlossene Fonds melden einen Stammaktienanteil von 6,4% an BioMarin Pharmaceuticals (BMRN). Zusammen besitzen die meldenden Personen wirtschaftlich 12.288.611 Aktien von insgesamt 192.001.650 ausstehenden Aktien zum 30. Juni 2025. Das Eigentum wird geteilt (kein alleiniges Stimm- oder Verfügungsrecht angegeben); die Bestände sind auf mehrere Viking-Einheiten und -Fonds verteilt (größte gemeldete Positionen: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). In der Einreichung wird angegeben, dass die Wertpapiere nicht zum Zweck des Wechsels oder der Beeinflussung der Kontrolle des Emittenten erworben wurden. Die Unterschriften der Änderung sind auf den 14. August 2025 datiert.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G



VIKING GLOBAL INVESTORS LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Investors LP (1)(2)(3)
Date:08/14/2025
VIKING GLOBAL PERFORMANCE LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Performance LLC (1)(2)(3)
Date:08/14/2025
Viking Global Equities II LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Equities II LP (1)(2)(3)
Date:08/14/2025
Viking Global Equities Master Ltd.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)(3)
Date:08/14/2025
Viking Long Fund GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)(3)
Date:08/14/2025
Viking Long Fund Master Ltd.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Parent GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Liquid Portfolio Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Liquid Portfolio Sub-Master LP (1)(2)(3)
Date:08/14/2025
HALVORSEN OLE ANDREAS
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
Date:08/14/2025
Ott David C.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
Date:08/14/2025
Shabet Rose Sharon
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
Date:08/14/2025

Comments accompanying signature: (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
Exhibit Information

EXHIBIT A - JOINT FILING AGREEMENT

FAQ

How many BioMarin (BMRN) shares do Viking-affiliated Reporting Persons beneficially own?

The Reporting Persons beneficially own 12,288,611 shares of BioMarin common stock as reported in this Schedule 13G/A.

What percentage of BioMarin does the 12,288,611-share position represent?

The position represents 6.4% of BioMarin's common stock based on 192,001,650 shares outstanding as of June 30, 2025.

Do any Viking Reporting Persons have sole voting or dispositive power over the shares?

No. The filing reports 0 shares with sole voting power and 0 shares with sole dispositive power; all reported authority is shared.

Was the stake acquired to influence control of BioMarin?

According to the certification in Item 10, the Reporting Persons state the securities were not acquired to change or influence control of the issuer.

Which Viking entities hold the largest reported BioMarin positions?

Largest reported positions include Viking Global Investors LP (12,288,611 beneficially attributable), Viking Global Performance LLC (8,208,825), and Viking Global Equities Master Ltd. (8,044,650).
Biomarin Pharmaceutical Inc

NASDAQ:BMRN

BMRN Rankings

BMRN Latest News

BMRN Latest SEC Filings

BMRN Stock Data

11.23B
190.52M
0.78%
98.61%
2.68%
Biotechnology
Pharmaceutical Preparations
United States
NOVATO